The Efficacy of standard treatment and dimethyl fumarate in the treatment of patients with COVID-19

Babol University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月1日

试验速览

暂无简介。

•Men and women of at least 18 years of age capable of providing informed consent
•Confirmation of COVID-19 with RT-PCR
•Need for hospitalization
•No need for mechanical ventilation
•No need to more than 10 L/min of supplemental oxygen by any device.
•The patient must meet at least one of the following high-risk criteria: age 70 years or older, obesity (BMI = 30 kg/m2), diabetes mellitus, uncontrolled blood pressure (systolic blood pressure> 150 mm Hg), history of respiratory disease (Including asthma or COPD), history of heart failure, history of coronary artery disease, fever > 38.4°C in the last 48 hours, shortness of breath at the time of referral, Bicytopenia, Pancytopenia, or a combination of neutrophilia and lymphopenia

•History of allergy to dimethyl fumarate
•Use of dimethyl fumarate before current hospitalization
•Patients more than 70 years of age with a history of any of the following in the last six months: Class III / IV Heart Failure Based on the New York Heart Association (NYHA) classification, Insulin-dependent diabetes, Angina pectoris, Malignancy
•Uncontrolled bacterial, fungal, or viral infection (other than COVID-19).
•Any history of receiving convalescent plasma therapy
•Absolute neutrophil count (ANC) < 500
•Platelets count < 50,000
•Pregnant women or those intending to become pregnant
•Breastfeeding women
•AST or ALT > 5 times the upper limits of normal (ULN)
•Estimated glomerular filtration rate (eGFR) < 30 ml/min in 1.73 m2 using MDRD equation

发起方